Stoke Therapeutics (NASDAQ:STOK) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Stoke Therapeutics (NASDAQ:STOK) released its quarterly earnings data on Tuesday. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.05, Zacks reports. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The firm had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million.

Stoke Therapeutics Stock Up 0.2 %

Stoke Therapeutics stock traded up $0.02 during mid-day trading on Thursday, hitting $13.27. 280,079 shares of the company were exchanged, compared to its average volume of 760,807. Stoke Therapeutics has a 1-year low of $3.77 and a 1-year high of $17.58. The business has a fifty day moving average of $13.24 and a 200 day moving average of $13.70. The company has a market capitalization of $698.64 million, a PE ratio of -6.09 and a beta of 0.95.

Wall Street Analysts Forecast Growth

STOK has been the subject of several recent research reports. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Friday, October 11th. Leerink Partners started coverage on Stoke Therapeutics in a research note on Monday, October 14th. They set an “outperform” rating and a $18.00 price target for the company. Wedbush reissued an “outperform” rating and issued a $17.00 price objective on shares of Stoke Therapeutics in a research note on Thursday, July 11th. Needham & Company LLC restated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Wednesday. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Stoke Therapeutics has a consensus rating of “Buy” and a consensus price target of $20.83.

Insider Buying and Selling

In related news, major shareholder Skorpios Trust sold 1,937,500 shares of the firm’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the completion of the sale, the insider now directly owns 8,906,181 shares of the company’s stock, valued at $125,131,843.05. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 11.30% of the stock is currently owned by corporate insiders.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.